» Authors » Trine-Lise Larsen

Trine-Lise Larsen

Explore the profile of Trine-Lise Larsen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 24
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Svalastoga M, Larsen T, Brekke J, Enden T, Froen H, Garresori H, et al.
Front Oncol . 2025 Feb; 15:1520725. PMID: 39931081
Introduction: It is unclear how drug-interaction with apixaban influences recurrent venous thromboembolism (VTE) and bleedings in cancer patients. Methods: A analysis of a single-arm interventional clinical trial on apixaban treatment...
2.
Ikdahl E, Rollefstad S, Kazemi A, Provan S, Larsen T, Semb A
Eur Heart J Cardiovasc Pharmacother . 2023 Oct; 10(1):27-34. PMID: 37881093
Aims: Patients with inflammatory joint diseases (IJD), including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) have increased rates of pulmonary embolism (PE). Non-steroidal anti-inflammatory drugs (NSAIDs) use...
3.
Hussaini P, Larsen T, Ghanima W, Dahm A
Thromb Haemost . 2023 Oct; 124(4):351-362. PMID: 37816388
Background:  Incidence of and risk factors for bleeding in cancer patients with venous thromboembolism (VTE) treated with apixaban are poorly described. Methods:  We analyzed data from the prospective CAP study...
4.
Larsen T, Svalastoga M, Brekke J, Enden T, Froen H, Garresori H, et al.
Thromb Res . 2023 Jun; 228:128-133. PMID: 37327527
Introduction: In a recent interventional study of cancer patients with newly diagnosed venous thrombosis (VT), we found a high risk of arterial thrombotic events (AT) during treatment with therapeutic doses...
5.
Larsen T, Ghanima W, Sandset P, Froen H, Jacobsen E, Torfoss D, et al.
Tidsskr Nor Laegeforen . 2023 Jan; 142(1). PMID: 36655971
Venous thromboembolism is a common complication of cancer. The prevalence varies according to cancer type and increases proportionally with the stage of cancer. In the past 15-20 years, low molecular...
6.
Larsen T, Garresori H, Brekke J, Enden T, Froen H, Jacobsen E, et al.
J Thromb Haemost . 2022 Jul; 20(8):1937-1939. PMID: 35859282
No abstract available.
7.
Larsen T, Garresori H, Brekke J, Enden T, Froen H, Jacobsen E, et al.
J Thromb Haemost . 2022 Feb; 20(5):1166-1181. PMID: 35114046
Background: There are no data on the effect of low-dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low-dose apixaban...
8.
Torheim E, Ndhlovu L, Pettersen F, Larsen T, Jha A, Torgersen K, et al.
Eur J Immunol . 2009 Apr; 39(5):1280-7. PMID: 19384871
Recent studies have indicated that Treg contribute to the HIV type 1 (HIV-1)-related immune pathogenesis. However, it is not clear whether T cells with suppressive properties reside within the HIV-1-specific...